Floatz logo

Anti-Cd7 Car-Pnk Cells

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Precursor T-Cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Sanofi
Phase 2B
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Isatuximab
Sanofi
Phase 2CCC
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Benadryl
Sanofi
Phase 2CCC

View all 19 →

Same molecule, other indications

Anti-Cd7 Car-Pnk Cells is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
48 / 100
View asset →
T-cell large granular lymphocyte leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →